{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:27:39Z","timestamp":1768458459274,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11604-021-01132-6","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T04:02:43Z","timestamp":1621569763000},"page":"984-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-7887","authenticated-orcid":false,"given":"Tanyaluck","family":"Thientunyakit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thonnapong","family":"Thongpraparn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakmeedaj","family":"Sethanandha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerasak","family":"Muangpaisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","volume":"15","author":"Alzheimer's Association","year":"2019","unstructured":"Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15:321\u201387.","journal-title":"Alzheimers Dement"},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/scitranslmed.3002369","volume":"3","author":"DM Holtzman","year":"2011","unstructured":"Holtzman DM, Morris JC, Goate AM. Alzheimer\u2019s disease: the challenge of the second century. Sci Transl Med. 2011;3:77.","journal-title":"Sci Transl Med"},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"1132_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"1132_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"1132_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16:661\u201376.","journal-title":"Lancet Neurol"},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. J Nucl Med. 2013;54:476\u201390.","journal-title":"J Nucl Med"},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58:1711\u20137.","journal-title":"J Nucl Med"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-180239","volume":"64","author":"Y-F Shea","year":"2018","unstructured":"Shea Y-F, Barker W, Greig-Gusto MT, Loewenstein DA, Duara R, DeKosky ST. Impact of amyloid PET imaging in the memory clinic: a systematic review and meta-analysis. J Alzheimers Dis. 2018;64:323\u201335.","journal-title":"J Alzheimers Dis"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00259-011-2045-0","volume":"39","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, et al. A\u03b2 Imaging: feasible, pertinent, and vital to progress in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39:209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med. 2010;51:913\u201320.","journal-title":"J Nucl Med"},{"key":"1132_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"1132_CR16","unstructured":"Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging. 1997; 18:S1\u2013S2"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031\u20138.","journal-title":"Neurology"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12149-020-01453-y","volume":"34","author":"T Thientunyakit","year":"2020","unstructured":"Thientunyakit T, Sethanandha C, Muangpaisan W, Chawalparit O, Arunrungvichian K, Siriprapa T, et al. Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer\u2019s disease. Ann Nucl Med. 2020;34:337\u201348.","journal-title":"Ann Nucl Med"},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1132_CR21","first-page":"661","volume":"45","author":"Train the Brain Forum Committee","year":"1993","unstructured":"Train the Brain Forum Committee. Thai mental state examination (TMSE). Siriraj Hosp Gaz. 1993;45:661\u201374.","journal-title":"Siriraj Hosp Gaz"},{"key":"1132_CR22","first-page":"916","volume":"98","author":"W Muangpaisan","year":"2015","unstructured":"Muangpaisan W, Assantachai P, Sitthichai K, Richardson K, Brayne C. The distribution of Thai Mental State Examination Scores among Non-Demented Elderly in Suburban Bangkok Metropolitan and Associated Factors. J Med Assoc Thai. 2015;98:916\u201324.","journal-title":"J Med Assoc Thai"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/psyg.12451","volume":"20","author":"H Phannarus","year":"2020","unstructured":"Phannarus H, Muangpaisan W, Siritipakorn P, Chotinaiwattarakul W. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson\u2019s disease, Parkinson\u2019s disease dementia, Alzheimer\u2019s disease, and normal cognition. Psychogeriatrics. 2020;20:20\u20137.","journal-title":"Psychogeriatrics"},{"key":"1132_CR24","unstructured":"Institute of Geriatric Medicine, Department of Medical Services, Ministry of Public Health. The association between MMSE-Thai 2002 and Thai Mini-Mental State Examination; TMSE in the screening for dementia in elderly. http:\/\/agingthai.dms.moph.go.th\/agingthai\/wp-content\/uploads\/2020\/04\/\u0e42\u0e04\u0e23\u0e07\u0e01\u0e32\u0e23\u0e1b\u0e23\u0e30\u0e40\u0e21\u0e34\u0e19\u0e40\u0e17\u0e04\u0e42\u0e19\u0e42\u0e25\u0e22\u0e35\u0e17\u0e32\u0e07\u0e01\u0e32\u0e23\u0e41\u0e1e\u0e17\u0e22\u0e4c.pdf (Thai). Accessed 10 Oct 2020"},{"key":"1132_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/01.JGP.0000192478.82189.a8","volume":"14","author":"R Perneczky","year":"2006","unstructured":"Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriat Psychiat. 2006;14:139\u201344.","journal-title":"Am J Geriat Psychiat"},{"key":"1132_CR26","unstructured":"Alzheimer\u2019s Disease Neuroimaging Initiative website. ADNI 2 PET technical procedures manual: Florbetapir. http:\/\/www.adni-info.org\/Scientists\/doc\/ADNI2_PET_Tech_Manual-Version_4_2014Oct27_CLEAN.pdf"},{"key":"1132_CR27","volume-title":"Statistical parametric mapping: the analysis of functional brain images","author":"WD Penny","year":"2007","unstructured":"Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. Statistical parametric mapping: the analysis of functional brain images. London: Elsevier; 2007."},{"key":"1132_CR28","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1007\/s00259-011-1905-y","volume":"38","author":"E Prieto","year":"2011","unstructured":"Prieto E, Collantes M, Delgado M, Juri C, Garc\u00eda-Garc\u00eda L, Molinet F, et al. Statistical parametric maps of 18 F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study. Eur J Nucl Med Mol Imaging. 2011;38:2228\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1132_CR29","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1093\/brain\/aws125","volume":"135","author":"G Jones","year":"2012","unstructured":"Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, et al. Regional dynamics of amyloid-b deposition in healthy elderly, mild cognitive impairment and Alzheimer\u2019s disease: a voxelwise PiB\u2013PET longitudinal study. Brain. 2012;135:2126\u201339.","journal-title":"Brain"},{"key":"1132_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53:378\u201384.","journal-title":"J Nucl Med"},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"V Camus","year":"2012","unstructured":"Camus V, Payoux P, Barr\u00e9 L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18 F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00259-015-3115-5","volume":"42","author":"K Chiotis","year":"2015","unstructured":"Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. Eur J Nucl Med Mol Imaging. 2015;42:1492\u2013506.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1132_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72\u201383.","journal-title":"Alzheimers Dement"},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12149-015-0978-2","volume":"29","author":"C Namiki","year":"2015","unstructured":"Namiki C, Takita Y, Iwata A, Momose T, Senda M, Okubo Y, et al. Imaging characteristics and safety of florbetapir (18 F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer\u2019s disease. Ann Nucl Med. 2015;29:570\u201381.","journal-title":"Ann Nucl Med"},{"key":"1132_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00259-012-2237-2","volume":"40","author":"A Nordberg","year":"2013","unstructured":"Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2013;40:104\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1132_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid \u03b2 in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129\u201335.","journal-title":"Lancet Neurol"},{"key":"1132_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2967\/jnumed.112.107185","volume":"54","author":"GA Becker","year":"2013","unstructured":"Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to \u03b2-amyloid deposits in human brains. J Nucl Med. 2013;54:723\u201331.","journal-title":"J Nucl Med"},{"key":"1132_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"1132_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"1132_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12149-017-1154-7","volume":"31","author":"T Miki","year":"2017","unstructured":"Miki T, Shimada H, Kim J-S, Yamamoto Y, Sugino M, Kowa H, et al. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer\u2019s disease, subjects with amnestic mild cognitive impairment and healthy volunteers. Ann Nucl Med. 2017;31:260\u201372.","journal-title":"Ann Nucl Med"},{"key":"1132_CR42","first-page":"27","volume-title":"Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Advances in pharmacology","author":"AD Cohen","year":"2012","unstructured":"Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Advances in pharmacology. Amsterdam: Elsevier; 2012. p. 27\u201381."},{"issue":"11","key":"1132_CR43","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. \u03b2-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer\u2019s disease. Brain. 2007;130(11):2837\u201344.","journal-title":"Brain"},{"issue":"3","key":"1132_CR44","first-page":"279","volume":"76","author":"T Thientunyakit","year":"2021","unstructured":"Thientunyakit T, Sethanandha C, Muangpaisan W, Minoshima S. 3D-SSP analysis for amyloid brain PET imaging using [18F]florbetapir in patients with Alzheimer\u2019s dementia and mild cognitive impairment. Med J Malays. 2021;76(3):279\u201387.","journal-title":"Med J Malays"},{"key":"1132_CR45","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1148\/rg.2018180160","volume":"38","author":"TF Lundeen","year":"2018","unstructured":"Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and artifacts in Amyloid PET. Radiographics. 2018;38:2123\u201333.","journal-title":"Radiographics"},{"key":"1132_CR46","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer\u2019s disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-021-01132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-021-01132-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-021-01132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T10:37:25Z","timestamp":1675334245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-021-01132-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s11604-021-01132-6","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest related to any aspect of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}